<DOC>
	<DOCNO>NCT00966706</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , capecitabine , gemcitabine hydrochloride , epirubicin hydrochloride , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know whether cisplatin , capecitabine , gemcitabine hydrochloride effective give together epirubicin hydrochloride docetaxel treat patient advanced metastatic pancreatic cancer . PURPOSE : This randomized phase II trial study side effect give cisplatin , capecitabine , gemcitabine hydrochloride together epirubicin hydrochloride compare give cisplatin , capecitabine , gemcitabine hydrochloride together docetaxel see well work treat patient stage III stage IV pancreatic cancer .</brief_summary>
	<brief_title>Cisplatin , Capecitabine , Gemcitabine Epirubicin Docetaxel Patients With Stage III IV Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess 6-months progression-free survival patient stage III IV adenocarcinoma pancreas treat cisplatin , capecitabine , gemcitabine hydrochloride ( PXG ) epirubicin hydrochloride v PXG docetaxel . - Evaluate activity toxicity regimens patient . OUTLINE : This multicenter study . Patients randomize 1 2 arm . - Arm I ( PEXG ) : Patients receive cisplatin , gemcitabine hydrochloride , docetaxel day 1 15 , capecitabine day 1-28 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Arm II ( PGDX ) : Patients receive cisplatin , gemcitabine hydrochloride , epirubicin hydrochloride day 1and 15 , capecitabine day 1-28 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients may undergo surgery tumor become resectable .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced metastatic adenocarcinoma pancreas Stage III IV disease Measurable disease No symptomatic brain metastasis PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Adequate bone marrow , liver , kidney function Not pregnant nursing No malignancy within past 5 year except surgically treat carcinoma situ cervix , basal squamous cell carcinoma skin No multiple severe disease compromise study safety , include follow : Cardiac failure Myocardial infarction within past 4 month Cardiac arrhythmia History psychiatric disability PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy pancreatic cancer No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>